Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
E. Unti, S. Mazzucchi, G. Palermo, U. Bonuccelli & R. Ceravolo. (2017) Antipsychotic drugs in Huntington’s disease. Expert Review of Neurotherapeutics 17:3, pages 227-237.
Read now
Read now
Thomas Müller. (2017) Investigational agents for the management of Huntington’s disease. Expert Opinion on Investigational Drugs 26:2, pages 175-185.
Read now
Read now
Sarah L Mason & Roger A Barker. (2016) Novel targets for Huntington’s disease: future prospects. Degenerative Neurological and Neuromuscular Disease 6, pages 25-36.
Read now
Read now
Kathleen M. Shannon. (2016) Pridopidine for the treatment of Huntington’s disease. Expert Opinion on Investigational Drugs 25:4, pages 485-492.
Read now
Read now
Sarah L Mason & Roger A Barker. (2016) Advancing pharmacotherapy for treating Huntington’s disease: a review of the existing literature. Expert Opinion on Pharmacotherapy 17:1, pages 41-52.
Read now
Read now
Articles from other publishers (45)
Huafei Yi, Jiao Ran, Yunzhu Tan, Zaofen Wang & Bingqian Liu. (2023) A colorimetric/electrochemical sensor based on coral-like CuCo2O4@AuNPs composites for sensitive dopamine detection. Analytical and Bioanalytical Chemistry.
Crossref
Crossref
Mohamad El Haj, Marie Caillaud, Ahmed Moustafa, Adriana Prundean, Clarisse Scherer, Christophe Verny & Philippe Allain. (2023) “Ten euros now” temporal discounting in Huntington disease. Neurological Sciences 44:8, pages 2763-2771.
Crossref
Crossref
Shuhei Shiino, Nelleke Corine van Wouwe, Scott A. Wylie, Daniel O. Claassen & Katherine E. McDonell. (2023) Huntington disease exacerbates action impulses. Frontiers in Psychology 14.
Crossref
Crossref
Josep Gamez, Matilde Calopa, Esteban Muñoz, Aileen Ferré, Oscar Huertas, Kevin McAllister, Núria Reig, Catherine Scart‐Grès, Raúl Insa & Jaime Kulisevsky. (2022) A proof‐of‐concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease. British Journal of Clinical Pharmacology 89:5, pages 1656-1664.
Crossref
Crossref
Francesco D’Egidio, Vanessa Castelli, Annamaria Cimini & Michele d’Angelo. (2023) Cell Rearrangement and Oxidant/Antioxidant Imbalance in Huntington’s Disease. Antioxidants 12:3, pages 571.
Crossref
Crossref
Marie-Claire Davis, Aron T. Hill, Paul B. Fitzgerald, Julie C. Stout & Kate E. Hoy. (2022) Motivationally salient cue processing measured using the monetary incentive delay (MID) task with electroencephalography (EEG): A potential marker of apathy in Huntington's disease. Neuropsychologia 177, pages 108426.
Crossref
Crossref
Samuel Frank, Claudia Testa, Mary C. Edmondson, Jody Goldstein, Elise Kayson, Blair R. Leavitt, David Oakes, Christine O’Neill, Christina Vaughan, Jacquelyn Whaley, Nicholas Gross, Mark Forrest Gordon, Juha-Matti Savola, Samuel Frank, Claudia Testa, David Stamler, Elise Kayson, Mary C. Edmondson, Blair R. Leavitt, David Oakes, Christine O’Neill, Christina Vaughan, Jody Goldstein, Margaret Bockus, Stephanie Leyva, Victoria Snively, Jacquelyn Whaley, Cynthia Wong, William M. Mallonee, Gregory Suter, Joseph Jankovic, Joohi Jimenez-Shahed, Christine Hunter, Daniel O. Claassen, Lauren West, Olivia Roman, Victor Sung, Jenna Smith, Ronda Clouse, Marie Saint-Hilaire, Denyse Turpin, Raymond James, Ramon Rodriguez, Kyle Rizer, Karen Anderson, Hope Heller, Alexis Ahmad, Susan Criswell, Brad A. Racette, Frederick C. Nucifora Jr, Gregory Churchill, MaryJane Ong, Tilak Mendis, Neila Mendis, Carlos Singer, Jane S. Paulsen, Jane Kerr, Richard Dubinsky, Carolyn Gray, Stewart A. Factor, Elaine Sperin, Eric Molho, Sharon Evans, Breanna Nickels, Courtney Bergen, Jessica Jaynes, Christina Reeves, Vicki Segro, Ali Samii, Emily Christopher, Debra Del Castillo, Sylvain Chouinard, Peggy Perry-Trice, Sherali Esmail, Wai Lun Alan Fung, Clare Gibbons, Amy Colcher, Cory Hackmyer, Andrew McGarry, Kevin Klos, Mark Gudesblatt, Daniel Schneider, Rohit Dhall, Edith Simpson, Joanne Wojcieszek, Andrea Hurt, Kathrin LaFaver, Annette Robinson, Fredy J. Revilla, Andrew P. Duker, Erin Neefus, Hilary Wilson-Perez, David Shprecher, Tyler Hohnholt, Paola Wall, James Boyd, Emily Houston, Eric S. Farbman, Shamine Poynor, Pinky Agarwal, Julissa Leon, Shirley Eberly, Arthur Watts, Pierre Tariot, Andrew Feigin, Scott R. Evans & Christopher A. Beck. (2022) The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study. CNS Drugs 36:11, pages 1207-1216.
Crossref
Crossref
Bandna Gupta & Kopal Rohatgi. 2022. Neurodegenerative Diseases: Multifactorial Degenerative Processes, Biomarkers and Therapeutic Approaches (First Edition). Neurodegenerative Diseases: Multifactorial Degenerative Processes, Biomarkers and Therapeutic Approaches (First Edition)
218
260
.
Lee‐Anne Morris, Claire O'Callaghan & Campbell Le Heron. (2022) Disordered Decision Making: A Cognitive Framework for Apathy and Impulsivity in Huntington's Disease. Movement Disorders 37:6, pages 1149-1163.
Crossref
Crossref
Maria Judit Molnar, Viktor Molnar, Mariann Fedor, Reka Csehi, Karoly Acsai, Beata Borsos & Zoltan Grosz. (2022) Improving Mood and Cognitive Symptoms in Huntington's Disease With Cariprazine Treatment. Frontiers in Psychiatry 12.
Crossref
Crossref
Jordyn M. Wilcox, David C. Consoli, Krista C. Paffenroth, Brittany D. Spitznagel, Erin S. Calipari, Aaron B. Bowman & Fiona E. Harrison. (2022) Manganese-induced hyperactivity and dopaminergic dysfunction depend on age, sex and YAC128 genotype. Pharmacology Biochemistry and Behavior 213, pages 173337.
Crossref
Crossref
Mingan Li, Lin Zhou, Xiaohui Sun, Yunqi Yang, Ce Zhang, Tian Wang & Fenghua Fu. (2022) Dopamine, a co-regulatory component, bridges the central nervous system and the immune system. Biomedicine & Pharmacotherapy 145, pages 112458.
Crossref
Crossref
Yijing Bai, Long Niu, Song Li & Weidong Le. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
4271
4301
.
Neha Sawant, Hallie Morton, Sudhir Kshirsagar, Arubala P. Reddy & P. Hemachandra Reddy. (2021) Mitochondrial Abnormalities and Synaptic Damage in Huntington’s Disease: a Focus on Defective Mitophagy and Mitochondria-Targeted Therapeutics. Molecular Neurobiology 58:12, pages 6350-6377.
Crossref
Crossref
Chumki Dalal, Anjali Kumari Garg & Sumit Kumar Sonkar. (2021) β-Cyclodextrin-capped ZnO-doped carbon dot as an advanced fluorescent probe for selective detection of dopamine. New Journal of Chemistry 45:45, pages 21299-21307.
Crossref
Crossref
Francesca Chiara Pignalosa, Antonella Desiderio, Paola Mirra, Cecilia Nigro, Giuseppe Perruolo, Luca Ulianich, Pietro Formisano, Francesco Beguinot, Claudia Miele, Raffaele Napoli & Francesca Fiory. (2021) Diabetes and Cognitive Impairment: A Role for Glucotoxicity and Dopaminergic Dysfunction. International Journal of Molecular Sciences 22:22, pages 12366.
Crossref
Crossref
Anand Kumar Sahu & Ashok Kumar Mishra. (2021) Interaction of Dopamine with Zwitterionic DMPC and Anionic DMPS Multilamellar Vesicle Membranes. Langmuir 37:45, pages 13430-13443.
Crossref
Crossref
Andrew Kisling, Shannon Byrne, Rohan U. Parekh, Deepthy Melit-Thomas, Lisandra E. de Castro Brás, Robert M. Lust, Stefan Clemens, Srinivas Sriramula & Laxmansa C. Katwa. (2021) Loss of Function in Dopamine D3 Receptor Attenuates Left Ventricular Cardiac Fibroblast Migration and Proliferation in vitro. Frontiers in Cardiovascular Medicine 8.
Crossref
Crossref
Ryoma Morigaki, Jannifer H. Lee, Tomoko Yoshida, Christian Wüthrich, Dan Hu, Jill R. Crittenden, Alexander Friedman, Yasuo Kubota & Ann M. Graybiel. (2020) Spatiotemporal Up-Regulation of Mu Opioid Receptor 1 in Striatum of Mouse Model of Huntington’s Disease Differentially Affecting Caudal and Striosomal Regions. Frontiers in Neuroanatomy 14.
Crossref
Crossref
Giovanni Palermo, Sonia Mazzucchi, Elisa Unti, Ubaldo Bonuccelli & Roberto Ceravolo. (2020) Tardive Syndrome Associated With Tetrabenazine in Huntington Disease. Journal of Clinical Psychopharmacology 40:6, pages 628-630.
Crossref
Crossref
Abdolhamid Hatefi-Mehrjardi, Mohammad Ali Karimi, Mahdiyeh Soleymanzadeh & Azam Barani. (2020) Highly sensitive detection of dopamine, ascorbic and uric acid with a nanostructure of dianix yellow/multi-walled carbon nanotubes modified electrode. Measurement 163, pages 107893.
Crossref
Crossref
Miguel Perez de la Mora, Carlos Hernandez-Mondragon, Minerva Crespo-Ramirez, José Rejon-Orantes, Dasiel O. Borroto-Escuela & Kjell Fuxe. (2020) Conventional and Novel Pharmacological Approaches to Treat Dopamine-Related Disorders: Focus on Parkinson’s Disease and Schizophrenia. Neuroscience 439, pages 301-318.
Crossref
Crossref
Mohamed S. Abdelfattah, Sherif E. A. Badr, Sally A. Lotfy, Gouda H. Attia, Ahmed M. Aref, Ahmed E. Abdel Moneim & Rami B. Kassab. (2019) Rutin and Selenium Co-administration Reverse 3-Nitropropionic Acid-Induced Neurochemical and Molecular Impairments in a Mouse Model of Huntington’s Disease. Neurotoxicity Research 37:1, pages 77-92.
Crossref
Crossref
Yijing Bai, Long Niu, Song Li & Weidong Le. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
31
.
Craig T. Werner, Christopher J. Williams, Mercedes R. Fermelia, Da-Ting Lin & Yun Li. (2019) Circuit Mechanisms of Neurodegenerative Diseases: A New Frontier With Miniature Fluorescence Microscopy. Frontiers in Neuroscience 13.
Crossref
Crossref
Christiana C. Christodoulou, George Minadakis, Christiana Demetriou, Eleni Zamba-Papanicolaou & George Spyrou. (2019) Computational Identification of Metabolites for Pathways Related to Huntington's Disease. Computational Identification of Metabolites for Pathways Related to Huntington's Disease.
Sonia Lavisse, Susannah Williams, Sophie Lecourtois, Nadja van Camp, Martine Guillermier, Pauline Gipchtein, Caroline Jan, Sébastien Goutal, Leopold Eymin, Julien Valette, Thierry Delzescaux, Anselme L. Perrier, Philippe Hantraye & Romina Aron Badin. (2019) Longitudinal characterization of cognitive and motor deficits in an excitotoxic lesion model of striatal dysfunction in non-human primates. Neurobiology of Disease 130, pages 104484.
Crossref
Crossref
Akihiro Koreki, Takaki Maeda, Tsukasa Okimura, Yuri Terasawa, Toshiaki Kikuchi, Satoshi Umeda, Shiro Nishikata, Tatsuhiko Yagihashi, Mari Kasahara, Chiyoko Nagai, Yasushi Moriyama, Ryosuke Den, Tamotsu Watanabe, Hirotsugu Kikumoto, Motoichiro Kato & Masaru Mimura. (2019) Dysconnectivity of the Agency Network in Schizophrenia: A Functional Magnetic Resonance Imaging Study. Frontiers in Psychiatry 10.
Crossref
Crossref
Zayakhuu Gerelkhuu, Dasom Jung, Bui The Huy, Salah M. Tawfik, Maxwell L. Conte, Eric D. Conte & Yong-Ill Lee. (2019) Highly selective and sensitive detection of catecholamines using NaLuGdF4:Yb3+/Er3+ upconversion nanoparticles decorated with metal ions. Sensors and Actuators B: Chemical 284, pages 172-178.
Crossref
Crossref
Musthafa Mohamed Essa, Marzieh Moghadas, Taher Ba-Omar, M. Walid Qoronfleh, Gilles J. Guillemin, Thamilarasan Manivasagam, Arokiasamy Justin-Thenmozhi, Bipul Ray, Abid Bhat, Saravana Babu Chidambaram, Amanda J Fernandes, Byoung-Joon Song & Mohammed Akbar. (2019) Protective Effects of Antioxidants in Huntington’s Disease: an Extensive Review. Neurotoxicity Research 35:3, pages 739-774.
Crossref
Crossref
Manon Auffret, Sophie Drapier & Marc Vérin. (2019) New tricks for an old dog: A repurposing approach of apomorphine. European Journal of Pharmacology 843, pages 66-79.
Crossref
Crossref
Weichun Yang, Ziyi Shen, Sixian Wen, Wei Wang & Minyu Hu. (2018) Mechanisms of multiple neurotransmitters in the effects of Lycopene on brain injury induced by Hyperlipidemia. Lipids in Health and Disease 17:1.
Crossref
Crossref
Ga-Young Lee, Sundas Munir & Soo-Young Park. (2018) Label-Free Detection of Dopamine based on Photoluminescence of Boronic Acid-Functionalized Carbon Dots in Solid-State Polyethylene Glycol Thin Film. Macromolecular Research 26:12, pages 1150-1159.
Crossref
Crossref
Emily J Martin, Christina L Vaughan, Rabia Atayee, Jeremy M Hirst, Kaitlyn O’Donnell & Kyle P Edmonds. (2018) Hydromorphone-induced chorea as an atypical presentation of opioid neurotoxicity: A case report and review of the literature. Palliative Medicine 32:9, pages 1529-1532.
Crossref
Crossref
Audrey S. Dickey & Albert R. La Spada. (2017) Therapy development in Huntington disease: From current strategies to emerging opportunities. American Journal of Medical Genetics Part A 176:4, pages 842-861.
Crossref
Crossref
Susanna Waters, Joakim Tedroff, Henrik Ponten, Daniel Klamer, Clas Sonesson & Nicholas Waters. (2018) Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington’s Disease. Journal of Huntington's Disease 7:1, pages 1-16.
Crossref
Crossref
Yu-Kuan Lin & Yi-Chun Yeh. (2017) Dual-Signal Microbial Biosensor for the Detection of Dopamine without Inference from Other Catecholamine Neurotransmitters. Analytical Chemistry 89:21, pages 11178-11182.
Crossref
Crossref
Melanie Alpaugh, Danny Galleguillos, Juan Forero, Luis Carlos Morales, Sebastian W Lackey, Preeti Kar, Alba Di Pardo, Andrew Holt, Bradley J Kerr, Kathryn G Todd, Glen B Baker, Karim Fouad & Simonetta Sipione. (2017) Disease‐modifying effects of ganglioside GM1 in Huntington's disease models. EMBO Molecular Medicine 9:11, pages 1537-1557.
Crossref
Crossref
Jian Fang, Zhigang Xie, Gordon Wallace & Xungai Wang. (2017) Co-deposition of carbon dots and reduced graphene oxide nanosheets on carbon-fiber microelectrode surface for selective detection of dopamine. Applied Surface Science 412, pages 131-137.
Crossref
Crossref
Ryoma Morigaki & Satoshi Goto. (2017) Striatal Vulnerability in Huntington’s Disease: Neuroprotection Versus Neurotoxicity. Brain Sciences 7:12, pages 63.
Crossref
Crossref
Man Shan Yu & Naoko Tanese. (2017) Huntingtin Is Required for Neural But Not Cardiac/Pancreatic Progenitor Differentiation of Mouse Embryonic Stem Cells In vitro. Frontiers in Cellular Neuroscience 11.
Crossref
Crossref
Emma M. Coppen & Raymund A. C. Roos. (2016) Current Pharmacological Approaches to Reduce Chorea in Huntington’s Disease. Drugs 77:1, pages 29-46.
Crossref
Crossref
Ruth de Diego-Balaguer, Catherine Schramm, Isabelle Rebeix, Emmanuel Dupoux, Alexandra Durr, Alexis Brice, Perrine Charles, Laurent Cleret de Langavant, Katia Youssov, Christophe Verny, Vincent Damotte, Jean-Philippe Azulay, Cyril Goizet, Cl?mence Simonin, Christine Tranchant, Patrick Maison, Amandine Rialland, David Schmitz, Charlotte Jacquemot, Bertrand Fontaine & Anne-Catherine Bachoud-L?vi. (2016) COMT Val158Met Polymorphism Modulates Huntington's Disease Progression. PLOS ONE 11:9, pages e0161106.
Crossref
Crossref
Dan P. Covey, Hannah M. Dantrassy, Natalie E. Zlebnik, Iness Gildish & Joseph F. Cheer. (2016) Compromised Dopaminergic Encoding of Reward Accompanying Suppressed Willingness to Overcome High Effort Costs Is a Prominent Prodromal Characteristic of the Q175 Mouse Model of Huntington's Disease. The Journal of Neuroscience 36:18, pages 4993-5002.
Crossref
Crossref
Nelleke C. van Wouwe, Kristen E. Kanoff, Daniel O. Claassen, K. Richard Ridderinkhof, Peter Hedera, Madaline B. Harrison & Scott A. Wylie. (2015) The Allure of High-Risk Rewards in Huntington’s disease. Journal of the International Neuropsychological Society 22:4, pages 426-435.
Crossref
Crossref